We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
1240-P: Dyslipidemia over Time in Youth with Type 2 Diabetes: The SEARCH for Diabetes in Youth Study.
- Authors
BRADY, RYAN P.; SHAH, AMY S.; JENSEN, ELIZABETH T.; STAFFORD, JEANETTE M.; DAGOSTINO JR., RALPH; DOLAN, LAWRENCE M.; KNIGHT, LISA M.; IMPERATORE, GIUSEPPINA; TURLEY, CHRISTINE B.; LIESE, ANGELA D.; URBINA, ELAINE M.; LAWRENCE, JEAN M.; PIHOKER, CATHERINE; MARCOVINA, SANTICA M.; DABELEA, DANA
- Abstract
Limited information exists regarding the evolution of dyslipidemia in youth with type 2 diabetes (T2D). Understanding dyslipidemia risk factors may influence treatment. We studied 212 youth with T2D not on lipid lowering therapy (68% female, 43% non-Hispanic black, mean age 14.9±2.7y at baseline, mean follow-up 7.0±2.0y). Dyslipidemia was defined as HDL-C<35mg/dL, LDL-C>100mg/dL, or triglycerides (TG)>150mg/dL. Progression was defined as normal lipids at baseline, dyslipidemia at follow-up; regression as dyslipidemia at baseline, normal at follow-up; stable abnormal as dyslipidemia at both; stable normal as normal at both. Associations of A1c and abdominal adiposity (waist to height ratio, WHtR) over time (area under the curve, AUC) with progression and stable abnormal were examined and relative risks estimated. HDL-C progressed, regressed, was stable normal and stable abnormal in 12%, 11%, 62%, and 14%, respectively. Corresponding LDL-C values were 16%, 13%, 43% and 29%; TG were 17%, 11%, 56% and 16%. Each 1% increase in A1c AUC was associated with 13% higher risk of TG>150mg/dL and 22% higher risk of LDL-C>100mg/dL, after adjusting for WHtR (Table). There were no significant associations with WHtR. In youth with T2D, 33% and 45% had progression or stable dyslipidemia of TG and LDL-C, respectively. Higher A1c over time is associated with worse TG and LDL-C, highlighting the importance of glycemic control. Disclosure: R.P. Brady: None. A.S. Shah: None. E.T. Jensen: None. J.M. Stafford: None. R. Dagostino: Consultant; Self; Amgen, AstraZeneca, Celgene, Daiichi Sankyo. L.M. Dolan: None. L.M. Knight: None. G. Imperatore: None. C.B. Turley: None. A.D. Liese: None. E.M. Urbina: None. J.M. Lawrence: None. C. Pihoker: None. S.M. Marcovina: None. D. Dabelea: None. Funding: Centers for Disease Control and Prevention (1U18DP006131, U18DP006133, U18DP006134, U18DP006136, U18DP006138, U18DP006139); National Institutes of Health (1UC4DK108173)
- Publication
Diabetes, 2020, Vol 69, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db20-1240-P